search this site
- home
- highlights
- sinclair at a glance
- growing our operations worldwide
- products:oral health
- products:dermatology
- chairman´s statement
- business review:operational
- business review:financial
- board of directors
- senior management
- directors´ report
- corporate governance report
- directors´ remuneration report
- independent auditors´ report
- consolidated income statement
- balance sheets
- statements of changes in shareholders´ equity
- cash flow statements
- notes to the financial statements
- 1. Accounting Policies
- 2. Financial risk management
- 3. Segmental information
- 4. Exceptional operating items
- 5. Operating profit/(loss)
- 6. Employees and Directors
- 7. Finance Income and costs
- 8. Taxation on Loss on ordinary activites
- 9. Loss for the financial year
- 10. Earnings/(Loss) per Share
- 11. Goodwill
- 12. Intangible assets
- 13. Property, plant and equipment
- 14. Investments
- 15. Inventories
- 16. Trade and other receivables
- 17. Trade and other payables
- 18. Borrowings
- 19. Non-current tax
- 20. Financial Instruments
- 21. Called-up share capital
- 22. Options and Warrants over Shares of Sinclair Pharma plc
- 23. Share-based payments
- 24. Other Reserves
- 25. Cash Flows from Operating Activities
- 26. Operating lease commitments
- 27. Capital Commitments
- 28. Related Party Transactions
- corporate advisors
24. OTHER RESERVES
Cumulative |
|||
translation |
Warrant |
||
reserve |
reserve |
Total |
|
| Group | £'000 |
£'000 |
£'000 |
| At 1 July 2006 | 63 |
686 |
749 |
| Exchange differences arising on translation of overseas subsidiaries | (478) |
— |
(478) |
| At 30 June 2007 | (415) |
686 |
271 |
| Exchange differences arising on translation of overseas subsidiaries | 3,927 |
— |
3,927 |
| At 30 June 2008 | 3,512 |
686 |
4,198 |
Warrant |
|
reserve |
|
| Company | £'000 |
| At 1 July 2006, 30 June 2007 and 30 June 2008 | 686 |
Warrant reserve
Other reserves arose on the grant of 784,875 warrants in settlement of the National Insurance liability on certain warrants and unapproved
share options that were issued by the Company.
During the year ended 30 June 2004, the Company entered into a joint election with the holders of certain warrants for the transfer of the employer’s National Insurance liability arising on the exercise of the warrants. In consideration for the transfer of this liability, the Company granted additional warrants over units to subscribe for shares, which, as at the date of grant, provided the warrant holders with a right to subscribe for 784,875 shares.
The warrants were granted at the same exercise price as the warrants that attracted the National Insurance liability, which was less than market value on the date of grant reflecting the value of the National Insurance liability transferred to the holders. Accordingly, the intrinsic value (the difference between market price and the grant price) was transferred from the National Insurance provision and is included in the warrant reserve, which is released to the profit and loss account reserve as the underlying warrants are exercised.